Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05999292 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Study of 68Ga-R8760
A Phase 1 study, sponsored by Radionetics Oncology.
- Terminated
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT05999292: Clinical Trial Phase 1 study, sponsored by Radionetics Oncology.
NCT05999292 is a Phase 1 study that was terminated before completion, run by Radionetics Oncology. The registered enrollment target is 11 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (82% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05999292, a Phase 1 study, was terminated before completion, sponsored by Radionetics Oncology.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
A Phase 1 Safety and Dosimetry Study of 68Ga-R8760 in Patients with Adrenocortical Carcinoma and Healthy Volunteers
Interventions
- DRUG 68Ga-R8760 injection at pre-defined dose levels
- DRUG 68Ga-R8760 injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2023-09-11 |
| Est. Completion | 2024-05-23 |
| Phase | Phase 1 |
Why NCT05999292 stopped before completion
NCT05999292 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (82% lower).
The record links to 0 conditions, and to 2 interventions - of which 68Ga-R8760 injection at pre-defined dose levels is the first listed.
NCT05999292 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05999292 about?
NCT05999292 is a clinical study titled "Phase 1 Study of 68Ga-R8760". A Phase 1 Safety and Dosimetry Study of 68Ga-R8760 in Patients with Adrenocortical Carcinoma and Healthy Volunteers
What is the current status of trial NCT05999292?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2023-09-11. Estimated completion is 2024-05-23.
What interventions are being tested in trial NCT05999292?
The interventions under investigation include: 68Ga-R8760 injection at pre-defined dose levels (DRUG), 68Ga-R8760 injection (DRUG).
Who is sponsoring clinical trial NCT05999292?
This trial is sponsored by Radionetics Oncology, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05999292's enrollment target sits among peer trials
11 1911th of 2000 higher than 88 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI